首页> 外国专利> USE OF UBE3A UBIQUITINATION PP2A ACTIVATING FACTOR PTPA IN TREATING ANGELMAN SYNDROME AND AUTISM

USE OF UBE3A UBIQUITINATION PP2A ACTIVATING FACTOR PTPA IN TREATING ANGELMAN SYNDROME AND AUTISM

机译：UBE3A泛素化PP2A激活因子PTPA在治疗安格曼综合症和自闭症中的应用

页面导航

摘要
著录项
相似文献

摘要

Provided is a use of Ube3a ubiquitination PP2A activating factor PTPA in treating angelman syndrome and autism. A new pathogenesis of angelman syndrome and/or autism or diseases related thereto is disclosed, i.e., the activity of phosphotyrosine phosphatase activating factors for protein phosphatase 2A is abnormal due to the lack or overexpression of Ube3a. Therefore, said factors can be used as target spots to develop medicines alleviating or treating angelman syndrome and/or autism or diseases related thereto. Said factors further can be used as markers for diagnosing and assessing angelman syndrome and/or autism or diseases related thereto.

机译：提供了Ube3a泛素化PP2A活化因子PTPA在治疗天使曼综合症和自闭症中的用途。公开了天使曼综合征和/或自闭症或与之有关的疾病的新发病机理，即由于缺乏或过表达Ube3a，磷酸酪氨酸磷酸酶活化因子对蛋白质磷酸酶2A的活性异常。因此，所述因子可以用作开发或减轻安格曼综合症和/或自闭症或与其相关的疾病的药物的靶点。所述因素还可以用作诊断和评估安格曼综合症和/或自闭症或与其相关的疾病的标记。

著录项

公开/公告号WO2020168850A1

专利类型
公开/公告日2020-08-27

原文格式PDF
申请/专利权人 CENTER FOR EXCELLENCE IN BRAIN SCIENCE AND INTELLIGENCE TECHNOLOGY CHINESE ACADEMY OF SCIENCES;
展开▼

申请/专利号WO2020CN70997
发明设计人 XIONG ZHIQI;WANG JIE;
展开▼

申请日2020-01-08
分类号A61K45;A61P43;A61P25/28;A61P25/14;C12Q1/42;C12Q1/6883;
国家 WO
入库时间 2022-08-21 11:09:43

相似文献

专利
外文文献
中文文献